Abstract |
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-α has been demonstrated. Moreover, high levels of IL-6 and TNF-α have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.
|
Authors | Carlo Perricone, Paola Triggianese, Elena Bartoloni, Giacomo Cafaro, Angelo F Bonifacio, Roberto Bursi, Roberto Perricone, Roberto Gerli |
Journal | Journal of autoimmunity
(J Autoimmun)
Vol. 111
Pg. 102468
(07 2020)
ISSN: 1095-9157 [Electronic] England |
PMID | 32317220
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Antiviral Agents
- Cytokines
- Immunosuppressive Agents
- Hydroxychloroquine
- Chloroquine
- tocilizumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Betacoronavirus
(drug effects)
- COVID-19
- Chloroquine
(therapeutic use)
- Coronavirus Infections
(drug therapy, pathology)
- Cytokines
(antagonists & inhibitors, blood)
- Humans
- Hydroxychloroquine
(therapeutic use)
- Immunomodulation
(drug effects)
- Immunosuppressive Agents
(therapeutic use)
- Pandemics
- Pneumonia, Viral
(drug therapy, pathology)
- SARS-CoV-2
|